Stockscreener 앱 받기
1.18
1.72%
0.02
Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스
Price to sales forward of Alzamend Neuro, Inc. – BOATS:ALZN - TradingView
ALZN Q2 2026 Earnings: Narrower-than-expected loss sparks positive market reactionFiscal Year Earnings - dars.gov.et
ALZN Q2 2026 Earnings: EPS Beat by 70% but No Revenue – Stock Jumps on SurpriseGuidance Upgrade Report - dars.gov.et
$Alzamend Neuro (ALZN.US)$ it be like that - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market SessionAlzamend Neuro (NASDAQ:ALZN), Vivos Ther - Benzinga
ALZN Q4'25 Earnings: EPS estimate is (0.67) USD - TradingView
Alzamend Neuro | DEF 14A: Definitive information statements - Moomoo
Alzamend Neuro, Inc. Actuals & Estimates (NASDAQ:ALZN) - TradingView
Alzamend Neuro, Inc. Actuals & Estimates (BOATS:ALZN) - TradingView
Price to book forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
ALZN Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
Price to sales forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
ALZN Q4'25 Earnings: revenue estimate is 0 USD - TradingView
ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss SurprisesFiscal Year Earnings - dars.gov.et
Alzamend Neuro Inc (ALZN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alzamend Neuro Inc (ALZN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alzamend Neuro Inc (ALZN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alzamend Neuro Inc (ALZN) Institutional Confidence - TradingKey
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro Inc (ALZN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alzamend Neuro Inc (ALZN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALZN Q1 2026 Earnings: Smaller-than-Expected Loss Drives Shares HigherEarnings Manipulation Risk - newsline.com
Alzamend Neuro, Inc. Financial Disclosures & SEC Filings - TradingView
ALZN Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 70% Positive SurpriseEarnings Revision Downgrade - newsline.com
Alzamend Neuro Shares Dip With AL001 Trial in Focus, Cash Concerns Linger - Bez Kabli
ALZN Q1 2026 Earnings: Significant EPS Beat Driven by Narrower-than-Expected LossOne-Time Loss Impact - newsline.com
Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent
Alzamend Neuro (ALZN) Gains 3.48% as Positive Momentum BuildsCash Secured Put - newsline.com
ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Management Amid Pre-Revenue PhaseSaaS Earnings Trends - The Legal Advocate
Alzamend Neuro Inc. (ALZN) Stalls Near Support: Consolidation or Caution for This Alzheimer’s Play?Momentum Factor - thelegaladvocate.com
ALZNAlzamend Neuro Inc Stock Price and Quote - Finviz
Alzamend Neuro Inc. (ALZN) Q1 2026 Earnings: Narrower-than-Expected Loss as Early-Stage Biotech Continues R&D FocusEarnings Quality Score - newsline.com
ALZN Q1 2026 Earnings: Narrowing Losses Beat Estimates by 70%EBITDA Estimate Trend - newsline.com
ALZN Q1 2026 Earnings: EPS Surpasses Estimates by Over 70%, Stock DeclinesEarnings Season Preview - The Legal Advocate
ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill
TradingKey - TradingKey
How Alzamend (ALZN) handles its debt maturity schedule | Q1 2026: Earnings Beat EstimatesTop Analyst Buy Signals - newser.com
Alzamend Neuro Inc. (ALZN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alzamend Neuro (ALZN) price target decreased by 10.71% to 25.50 - MSN
Alzamend (ALZN) Stock Swing Trade Setup (On the Radar) 2026-04-20Sector Rotation - Cổng thông tin điện tử tỉnh Lào Cai
Alzamend Neuro, Inc. 8-K Filing Details, NASDAQ Listing, and Corporate Information (April 17, 2026) - Minichart
Alzamend Neuro Shareholders Approve Governance and Capital Measures - The Globe and Mail
Shareholders of Alzamend Neuro (ALZN) approve board slate, plans and reverse split - Stock Titan
Director Milton Ault adds Alzamend Neuro (ALZN) shares in open-market buy - Stock Titan
CEO Moves: How sensitive is Alzamend Neuro Inc to inflationEarnings Overview Report & Smart Investment Allocation Tips - baoquankhu1.vn
Form PRE 14AOther preliminary proxy statements - ADVFN
Can Alzamend Neuro Inc disrupt its industryEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Aug Sectors: What is the dividend yield of Alzamend Neuro IncQuarterly Profit Review & Long-Term Safe Return Strategies - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - Sahm
In a 6-person study, new lithium therapy disturbed less brain chemistry - Stock Titan
2.64%
자본화:
|
볼륨(24시간):